Method of treating hyperproliferative vascular disease

Claim 1

A method of treating a hyperproliferative vascular disease selected from the group consisting of intimal smooth muscle cell proliferation, restenosis, and vascular occlusion, wherein the intimal smooth muscle cell proliferation, restenosis, or vascular occlusion is caused by an infectious disorder, hypothermia, or irradiation, which comprises administering an antiproliferative effective amount of rapamycin to said mammal orally, parenterally, intravascularly, intranasally, intrabronchially, transdermally, rectally, or via a vascular stent impregnated with rapamycin.

Claim 2

A method of treating a hyperproliferative vascular disease selected from the group consisting of intimal smooth muscle cell proliferation, restenosis, and vascular occlusion, wherein the intimal smooth muscle cell proliferation, restenosis, or vascular occlusion is caused by an infectious disorder, hypothermia, or irradiation, which comprises administering an antiproliferative effective amount of rapamycin to said mammal orally, parenterally, intravascularly, intranasally, intrabronchially, transdermally, rectally, or via a vascular stent impregnated with rapamycin.

Claim 3

A method of treating a hyperproliferative vascular disease selected from the group consisting of intimal smooth muscle cell proliferation, restenosis, and vascular occlusion, wherein the intimal smooth muscle cell proliferation, restenosis, or vascular occlusion is caused by vascular catheterization, vascular scraping, percutaneous transluminal/coronary angioplasty, vascular surgery, or laser treatment, which comprises, administering an antiproliferative effective amount of rapamycin to said mammal orally, parenterally, intravascularly, intranasally, intrabronchially, transdermally, rectally, or via a vascular stent impregnated with rapamycin.

Claim 4

A method of treating a hyperproliferative vascular disease selected from the group consisting of intimal smooth muscle cell proliferation, restenosis, and vascular occlusion, wherein the intimal smooth muscle cell proliferation, restenosis, or vascular occlusion is caused by vascular catheterization, vascular scraping, percutaneous transluminal/coronary angioplasty, vascular surgery, or laser treatment, which comprises, administering an antiproliferative effective amount of rapamycin to said mammal orally, parenterally, intravascularly, intranasally, intrabronchially, transdermally, rectally, or via a vascular stent impregnated with rapamycin.